CHENGDU, Chine, 28 août 2024 /PRNewswire/ — Keymed Biosciences Inc. (HKEX : 02162) a annoncé aujourd’hui ses résultats intermédiaires pour le premier semestre 2024, ainsi qu’une mise à jour corporative. Développement rapide de nos produits de pipeline Stapokibart (CM310) (anticorps…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.